HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways.

Abstract
Matrix-bound constituents, such as the small leucine-rich proteoglycan biglycan, can act as powerful signaling molecules when released by limited proteolysis of the extracellular matrix or de novo synthesized by macrophages in the circulation and body fluids. Specifically, biglycan acts as an endogenous ligand of innate immunity by directly engaging the Toll-like receptor (TLR)-2 and -4. In this study, we generated a transient transgenic mouse model where biglycan was de novo overproduced by hepatocytes driven by the albumin promoter. Transgenic biglycan was rapidly and abundantly synthesized by hepatocytes and released into the bloodstream. Notably, we found that circulating biglycan accumulated in the kidneys where it caused recruitment of leukocytes infiltrating the renal parenchyma concurrent with abnormal renal levels of chemoattractants CXCL1, CXCL2, CCL2 and CCL5. Using mice deficient in either TLR adapter proteins MyD88 or TRIF we discovered that MyD88 deficiency drastically reduced neutrophil and macrophage infiltration in the kidney, whereas TRIF deficiency decreased T cell infiltrates. Production of CXCL1, CXCL2 and CCL2 required MyD88, whereas the levels of T cell and macrophage attractant CCL5 required TRIF. Thus, we provide robust genetic evidence for circulating biglycan as a powerful pro-inflammatory mediator targeting the renal parenchyma. Furthermore, our results provide the first evidence that biglycan differentially triggers chemoattraction of leukocytes via two independent pathways, both under the control of TLR2/4, utilizing either MyD88 or TRIF adaptor proteins. As aberrant expression of biglycan occurs in several inflammatory diseases, this transient transgenic mouse model could serve as a valuable research tool in investigating the effects of increased biglycan expression in vivo and for the development of therapeutic strategies in the treatment of inflammatory diseases.
AuthorsJinyang Zeng-Brouwers, Janet Beckmann, Madalina-Viviana Nastase, Renato V Iozzo, Liliana Schaefer
JournalMatrix biology : journal of the International Society for Matrix Biology (Matrix Biol) Vol. 35 Pg. 132-42 (Apr 2014) ISSN: 1569-1802 [Electronic] Netherlands
PMID24361484 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 International Society of Matrix Biology. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Adaptor Proteins, Vesicular Transport
  • Biglycan
  • Chemotactic Factors
  • DNA Primers
  • Myd88 protein, mouse
  • Myeloid Differentiation Factor 88
  • TICAM-1 protein, mouse
  • Toll-Like Receptors
Topics
  • Adaptor Proteins, Vesicular Transport (deficiency, metabolism)
  • Analysis of Variance
  • Animals
  • Biglycan (biosynthesis, blood, genetics)
  • Blotting, Western
  • Chemotactic Factors (immunology)
  • DNA Primers (genetics)
  • Enzyme-Linked Immunosorbent Assay
  • Flow Cytometry
  • Hepatocytes (metabolism)
  • Immunohistochemistry
  • Inflammation (metabolism)
  • Kidney (immunology, metabolism)
  • Leukocytes (immunology)
  • Mice
  • Mice, Transgenic
  • Myeloid Differentiation Factor 88 (deficiency, metabolism)
  • Polymorphism, Restriction Fragment Length
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Toll-Like Receptors (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: